{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:34:22Z","timestamp":1790476462639,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ejim.2020.05.015","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T20:46:31Z","timestamp":1590698791000},"page":"66-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-9519","authenticated-orcid":false,"given":"Alberto","family":"Aimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Rapezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2020.05.015_bib0001","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.05.015_bib0002","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.05.015_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2019.07.022","article-title":"Cardiac amyloidosis: an underdiagnosed\/underappreciated disease","volume":"67","author":"Manolis","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2020.05.015_bib0004","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update","volume":"40","author":"Emdin","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.05.015_bib0005","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacbts.2019.02.002","article-title":"Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis","volume":"4","author":"Zhang","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.ejim.2020.05.015_bib0006","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijcard.2018.05.018","article-title":"Therapies for cardiac light chain amyloidosis: An update","volume":"271","author":"Aimo","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2020.05.015_bib0007","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2020.05.015_bib0008","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcmg.2019.03.026","article-title":"Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis","volume":"13","author":"Baggiano","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2020.05.015_bib0009","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/j.ejim.2018.07.026","article-title":"Minor salivary gland biopsy is more effective than normal appearing skin biopsy for amyloid detection in systemic amyloidosis: A prospective monocentric study","volume":"57","author":"Lecadet","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2020.05.015_bib0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejim.2018.05.029","article-title":"Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients","volume":"58","author":"Gonz\u00e1lez-Calle","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2020.05.015_bib0011","first-page":"1191","article-title":"The 1975 Declaration of Helsinki and consent","volume":"115","author":"Shephard","year":"1976","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.ejim.2020.05.015_bib0012","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/eurheartj\/eht150","article-title":"ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA)","volume":"34","author":"Brignole","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.05.015_bib0013","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJM198409273111303","article-title":"Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure","volume":"311","author":"Cohn","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2020.05.015_bib0014","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","article-title":"The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure","volume":"20","author":"Packer","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.05.015_bib0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/eurheartj\/16.suppl_F.4","article-title":"Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure","volume":"16","author":"Packer","year":"1995","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.05.015_bib0016","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1093\/eurheartj\/ehu204","article-title":"New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes","volume":"35","author":"Senni","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.05.015_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117332","article-title":"A systematic review concerning the relation between the sympathetic nervous system and heart failure with preserved left ventricular ejection fraction","volume":"10","author":"Verloop","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2020.05.015_bib0018","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/HJH.0000000000001856","article-title":"Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction","volume":"37","author":"Seravalle","year":"2019","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2020.05.015_bib0019","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijcard.2019.08.040","article-title":"Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction","volume":"296","author":"Vergaro","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2020.05.015_bib0020","doi-asserted-by":"crossref","first-page":"72a","DOI":"10.1016\/0735-1097(93)90466-E","article-title":"Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure","volume":"22","author":"Floras","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.05.015_bib0021","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/01.CIR.101.10.1130","article-title":"Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts","volume":"101","author":"Kawano","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2020.05.015_bib0022","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1006\/jmcc.2002.2088","article-title":"Molecular mechanisms of myocardial remodeling. The role of aldosterone","volume":"34","author":"Delcayre","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ejim.2020.05.015_bib0023","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1161\/01.CIR.91.10.2504","article-title":"Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition","volume":"91","author":"Cohn","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2020.05.015_bib0024","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejim.2018.05.004","article-title":"Management of the elderly patient with AL amyloidosis","volume":"58","author":"Nuvolone","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2020.05.015_bib0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10286-018-0514-2","article-title":"Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis)","volume":"29","author":"Gonzalez-Duarte","year":"2019","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.ejim.2020.05.015_bib0026","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.jcmg.2016.08.003","article-title":"Cardiac dysautonomia and survival in hereditary transthyretin amyloidosis","volume":"9","author":"Goldstein","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2020.05.015_bib0027","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.05.015_bib0028","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3348\/kjr.2015.16.2.286","article-title":"Propensity score matching: a conceptual review for radiology researchers","volume":"16","author":"Baek","year":"2015","journal-title":"Korean J Radiol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520302016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520302016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:32:18Z","timestamp":1760607138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620520302016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":28,"alternative-id":["S0953620520302016"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2020.05.015","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2020.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}